Last reviewed · How we verify
MT-7117
MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance.
MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance. Used for Pulmonary arterial hypertension (PAH).
At a glance
| Generic name | MT-7117 |
|---|---|
| Also known as | dersimelagon, Dersimelagon |
| Sponsor | Tanabe Pharma America, Inc. |
| Drug class | Soluble guanylate cyclase (sGC) activator |
| Target | Soluble guanylate cyclase (sGC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The drug directly activates soluble guanylate cyclase, an enzyme that produces cyclic guanosine monophosphate (cGMP), a key signaling molecule in vascular smooth muscle relaxation. By increasing cGMP levels, MT-7117 promotes vasodilation and reduces pulmonary vascular resistance, making it suitable for treating pulmonary hypertension. This mechanism is independent of nitric oxide availability, potentially offering benefits in patients with impaired nitric oxide signaling.
Approved indications
- Pulmonary arterial hypertension (PAH)
Common side effects
- Headache
- Dizziness
- Hypotension
Key clinical trials
- Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria (PHASE2)
- Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria (PHASE3)
- Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP (PHASE3)
- Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) (PHASE3)
- The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects. (PHASE1)
- Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects (PHASE1)
- Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MT-7117 CI brief — competitive landscape report
- MT-7117 updates RSS · CI watch RSS
- Tanabe Pharma America, Inc. portfolio CI